• Теги
    • избранные теги
    • Компании578
      • Показать ещё
      Разное135
      • Показать ещё
      Международные организации8
      • Показать ещё
      Страны / Регионы92
      • Показать ещё
      Показатели18
      • Показать ещё
      Люди14
      • Показать ещё
      Формат1
      Издания3
      Сферы1
Vertex Pharmaceuticals
27 февраля, 14:33

5 Toxic Stocks to Abandon or Play Short Right Now

In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.

22 февраля, 13:32

Bristol-Myers Squibb совершит обратный выкуп акций на сумму $2 млрд

Во вторник, 21 февраля, американский фармацевт Bristol-Myers Squibbобъявил о программе обратного выкупа акций на сумму $2 млрд. Представители компании добавили, что в ее совете директоров появилось три новых члена, в частности, бывший финансовый директор компании Bausch & Lomb Роберт Бертолини (Robert Bertolini), бывший CEO Vertex Pharmaceuticals, Shire Pharmaceuticals, а также Astra Merck Мэтью Эмменс (Matthew Emmens) и Теодор Сэмюэльс (Theodore Samuels), в настоящее время входящий в советы директоров фирм Perrigo Company и Stamps.com.

22 февраля, 09:14

Bristol-Myers Squibb совершит обратный выкуп акций на сумму $2 млрд

Во вторник, 21 февраля, американский фармацевт Bristol-Myers Squibbобъявил о программе обратного выкупа акций на сумму $2 млрд. Представители компании добавили, что в ее совете директоров появилось три новых члена, в частности, бывший финансовый директор компании Bausch & Lomb Роберт Бертолини (Robert Bertolini), бывший CEO Vertex Pharmaceuticals, Shire Pharmaceuticals, а также Astra Merck Мэтью Эмменс (Matthew Emmens) и Теодор Сэмюэльс (Theodore Samuels), в настоящее время входящий в советы директоров фирм Perrigo Company и Stamps.com.

13 февраля, 17:30

Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

10 февраля, 16:38

Biotech ETFs Powered by Q4 Earnings

Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

09 февраля, 16:09

5 Toxic Stocks to Dump or Play Short for Gains

Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.

31 января, 22:10

Top Analyst Reports for Alphabet, Citigroup, Chevron & Others

Top Analyst Reports for Alphabet, Citigroup, Chevron & Others

26 января, 17:36

Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up

Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.

Выбор редакции
25 января, 18:20

Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?

We expect Eli Lilly and Company (LLY) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.

25 января, 18:17

What Lies in Store for Pfizer (PFE) this Earnings Season?

Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.

25 января, 17:30

The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

25 января, 14:00

Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review

There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.

25 января, 00:04

Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

24 января, 16:51

Why Vertex (VRTX) Might Surprise This Earnings Season

Vertex (VRTX) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.

24 января, 16:14

Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?

The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.

Выбор редакции
24 января, 01:32

Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.

Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.

20 января, 22:41

4 Drug Stocks Poised to Surprise this Earnings Season

Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.

19 января, 16:37

Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

18 января, 20:38

Concert Offers Update on Cystic Fibrosis Drug, Stock Down

Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.